In fast-moving research spaces, anecdotes often travel faster than evidence. This Lab Notes entry breaks down the research ladder—anecdote, hypothesis, and evidence—and explains how thoughtful researchers evaluate information without confusing early signals for conclusions.
This Lab Notes post breaks down how to evaluate new peptide research without falling into hype cycles or impulse decisions.
It’s a guide to staying curious, disciplined, and safety-minded in a fast-moving research world.
Peptide Safety Guide: How to Biohack Responsibly in 2025
1. Next-Gen Delivery Platforms: Oral, Transdermal & Injectable Innovation A major 2025 review in Signal Transduction and Targeted Therapy highlights how peptide-based drugs are moving beyond traditional injections. Researchers are finding new ways to deliver peptides through oral, transdermal, and smart-carrier systems—making treatments easier and more accessible than ever. Key takeaways: 💡 Why this matters:For…
Why This Matters GLP-1 receptor agonists (like semaglutide, sold under brand names such as Wegovy and Ozempic) have transformed weight-loss medicine. But there’s been one big hurdle: they require weekly injections. For many people, that’s a deal-breaker. Now, oral GLP-1 options are entering late-stage development — and the results are starting to look promising. Could…
Why Antibiotic Resistance Matters Antibiotic resistance is a global health crisis. Drug-resistant infections already kill more than a million people each year, and by 2050 that number could climb to 10 million annually if new solutions aren’t found. Traditional antibiotics are failing because bacteria evolve faster than our drug pipelines can keep up. What we…
Meet ARA‑290, often overlooked among trendy peptides—but packed with intriguing science. Derived from erythropoietin (EPO) but without its red blood cell effects, this 11‑amino‑acid peptide targets the innate repair receptor, offering tissue protection and healing in various models. Discovery & Composition Pharmacokinetics Promising Findings Mechanistic Highlights Where It Stands Now Bottom Line Not flashy, but…
Antimicrobial resistance (AMR) is one of the biggest global health threats of our time. Standard antibiotics are losing effectiveness, bacteria are evolving faster than our drug pipelines, and the WHO has warned of millions of annual deaths if we don’t find alternatives. Now, a new breakthrough is turning heads: AI-designed antimicrobial peptides (AMPs). What Happened?…
1. Massive Therapeutic Peptide Dataset (58K+ Entries!) In 2025, researchers released a colossal dataset featuring 58,583 experimentally validated therapeutic peptides, each annotated with structural and functional data. Impressively, over 21,000 are multifunctional peptides, and more than 54,700 have structural details—either experimentally determined or predicted via tools like AlphaFold2 Nature.This treasure trove accelerates computational peptide discovery,…
1. Deep-Learning Unlocks Antimicrobial Self-Assembling Peptides A brand-new Nature Materials highlight (July 2025) features an AI-powered framework that discovers peptides capable of breaking down multidrug-resistant biofilms and treating intestinal bacterial infections in mice. These tiny agents assemble themselves into powerful antimicrobial structures—an inspiring fusion of AI and microbiology. Nature 2. Stanford’s Naturally Occurring Appetite-Suppressing Peptide…
No products in the cart.
